⏳ Fetching live dividend data...
Home › Calculator › PIRS Dividend Calculator 2026
Pieris Pharmaceuticals, Inc. · NASDAQ
Price: $13.60 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in PIRS → $77102.51M in 10 years · $6,382,823,284.95/month
Pieris Pharmaceuticals, Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to discovering and advancing drugs based on its proprietary Anticalin technology. These Anticalin proteins are therapeutic, low-molecular-weight molecules derived from naturally occurring human lipocalins, which are found in blood plasma and other bodily fluids. The company's pipeline includes several key drug candidates: Respiratory: PRS-060/AZD1402: A lead Anticalin candidate currently in Phase II clinical trials, targeting IL-4Ra for the treatment of asthma and various inflammatory diseases. PRS-220: An orally inhaled Anticalin protein designed to target connective tissue growth factor, intended for the treatment of idiopathic pulmonary fibrosis (IPF). Immuno-Oncology: Cinrebafusp alfa: A bispecific drug targeting both 4-1BB and HER2, developed for gastric cancers that express high or low levels of HER2. PRS-344/S095012: A bispecific Anticalin-antibody fusion protein in Phase I clinical trials, targeting 4-1BB and PD-L1 for various immuno-oncology indications. PRS-352: A preclinical-stage program focusing on undisclosed targets within immuno-oncology. Pieris has established several strategic partnerships, including collaboration and licensing agreements with Les Laboratoires Servier (and Institut de Recherches Internationales Servier), AstraZeneca AB, and Seagen Inc. Further licensing agreements are in place with the Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Additionally, the company has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Established in 2000, Pieris Pharmaceuticals, Inc. maintains its headquarters in Boston, Massachusetts.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open PIRS position with:
Real after-tax yield depends on where you live and how you hold PIRS.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 14.71% | 11.91% | $1,471 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 12.50% | 9.70% | $1,250 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 11.77% | 8.97% | $1,177 / yr |
| 🇬🇧 UK ISA | 0% | 14.71% | 11.91% | $1,471 / yr |
| 🇬🇧 UK Taxable | 8.75% | 13.42% | 10.62% | $1,342 / yr |
| 🇨🇦 TFSA | 0% | 14.71% | 11.91% | $1,471 / yr |
| 🇨🇦 CA Taxable | 25% | 11.03% | 8.23% | $1,103 / yr |
| 🇦🇺 Super (pension) | 15% | 12.50% | 9.70% | $1,250 / yr |
| 🇦🇺 AU Taxable | 30% | 10.30% | 7.50% | $1,030 / yr |
| 🇩🇪 DE Taxable | 26.375% | 10.83% | 8.03% | $1,083 / yr |
| 🇫🇷 FR Taxable | 30% | 10.30% | 7.50% | $1,030 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
PIRS pays quarterly — 4 times per year. Next ex-div: TBD.
How PIRS compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for PIRS sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2024-12-12 | 1 | $0.01 | — | ||
| A-Award | 2024-12-02 | 500 | $16.43 | $8.2K | ||
| Buy | 2024-08-07 | 1 | $1.00 | $1.00 | ||
| Buy | 2024-08-12 | 2,243 | $15.88 | $35.6K | ||
| Buy | 2024-08-09 | 3,000 | $14.89 | $44.7K | ||
| Buy | 2024-08-12 | 757 | $15.88 | $12.0K | ||
| A-Award | 2023-06-21 | 40,000 | $0.26 | $10.4K | ||
| A-Award | 2023-06-21 | 45,000 | $0.26 | $11.7K | ||
| A-Award | 2023-06-21 | 40,000 | $0.26 | $10.4K | ||
| A-Award | 2023-06-21 | 40,000 | $0.26 | $10.4K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the PIRS dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Pieris Pharmaceuticals, Inc. (PIRS) is currently trading at $13.60, 97% below its 52-week high. The current dividend yield is 14.71% based on an annual payout of $2.00 per share.
Pieris Pharmaceuticals, Inc. (PIRS) is a healthcare stock currently trading at $13.60 with a dividend yield of 14.71%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever